Business Wire

FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States

Some Lucentis patients have had detached retinas and serious infections inside the eye. If the eye becomes red, sensitive to light, or painful, or if there is a change in vision, patients should call ...
The Business Journals

Genentech's Lucentis eye drug works well in trial - but all eyes are on NIH study

The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight ...
Reuters

Study shows Lucentis safer than Avastin - Novartis

ZURICH, May 4 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday a new study showed that its Lucentis eye drug is safer than cancer drug Avastin for treating macular degeneration. Novartis said ...
The Business Journals

Genentech's Lucentis recommended for approval for diabetic eye disease

An FDA advisory panel recommended Thursday that Genentech Inc.'s eye drug Lucentis be approved for some diabetes patients who have lost their sight. An FDA advisory panel recommended Thursday that ...
Reuters

Study backs Roche's Avastin as cheap eye treatment

LONDON, June 11 (Reuters) - Roche's cancer drug Avastin is a cheap, effective treatment for preventing blindness and should be used routinely in countries that cannot afford the far more costly ...